Central 5-HT receptor hypersensitivity in migraine without aura

Cephalalgia

Volumn 23, Issue 1, 2003, Pages 29-34

  Cassidy, Eugene M ^a,c   Tomkins, E ^a   Dinan, T ^b   Hardiman, O ^a   O'Keane, V ^a  

^a BEAUMONT HOSPITAL   (Ireland)

^b University College Cork and INFANT Centre   (Ireland)

^c SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

5 HT1A; Migraine; Prolactin; Serotonin; Stress

Indexed keywords

BUSPIRONE; PROLACTIN; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN RECEPTOR;

ADULT; ANALYSIS OF VARIANCE; ANXIETY; ARTICLE; BECK DEPRESSION INVENTORY; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; FEMALE; HUMAN; MENSTRUAL CYCLE; MIGRAINE; NAUSEA; PROLACTIN BLOOD LEVEL; RECEPTOR SENSITIVITY; SEROTONINERGIC SYSTEM; SINGLE DRUG DOSE; VERTIGO; VOLUNTEER;

ADMINISTRATION, ORAL; ADULT; BUSPIRONE; FEMALE; HUMANS; MIDDLE AGED; MIGRAINE WITHOUT AURA; PROLACTIN; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; REFERENCE VALUES; SEROTONIN; SEROTONIN AGONISTS;

EID: 0037300593     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-2982.2003.00441.x     Document Type: Article

References (47)

1. Sicuteri F. Prophylactic and therapeutic properties of UML-491 in migraine. Int Arch Allergy 1959; 15:300-7.
2. Sicuteri F, Testi A, Anselmi B. Biochemical investigations in headache: increase in the hydroxyindoleacetic excretion during migraine attacks. Int Arch Allergy Appl Immunol 1961; 19:55-8.
3. Panconesi A, Sicuteri R. Headache induced by serotonergic agonists, a key to the interpretation of migraine pathogenesis? Cephalalgia 1997; 17:3-14.
4. Lance JW, Anthony M, Hinterberger H. The control of cranial arteries by humoral mechanisms and its relation to the migraine syndrome. Headache 1967; 7:93-102.
5. Weiller C, May A, Limmroth V, Juptner M, Kaube H, Schayck RV et al. Brainstem activation in spontaneous human migraine attacks. Nat Med 1995; 1:658-60.
6. Raskin NH, Hosobuchi Y, Lamb S. Headache may arise from perturbation of brain. Headache 1987; 27:416-20.
7. Veloso F, Kumar K. Deep brain implant migraine. J Neurol Neurosurg Psychiat 1996; 46 Suppl 7:A168-A169.
8. Chugani DC, Niimura K, Chaturvedi S, Muzik O, Fakhouri M, Lee M-L et al. Increased brain serotonin synthesis in migraine. Neurology 1999; 53:1473.
9. Pineyro G, Blier P. Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol Rev 1999; 51:533-91.
10. Breslau N, Chilcoat HP, Andreski P. Further evidence on the link between migraine and neuroticism. Neurology 1996; 47:663-7.
11. Breslau N, Merikangas K, Bowden CL. Comorbidity of migraine and major affective disorders. Neurology 1994; 44 Suppl 7:S17-S22.
12. Breslau N, Schultz LR, Stewart WF, Lipton RB, Lucia VC, Welch KMA. Headache and major depression. Is the association specific to migraine? Neurology 2000; 54:308-13.
13. Heisler LK, Chu HM, Brennan TJ, Danao JA, Bajwa P, Parsons LH et al. Elevated anxiety and anti-depressant-like responses in serotonin 5-HT1A receptor mutant mice. Proc Natl Acad Sci 1998; 95:15049-54.
14. Zhuang X, Gross C, Santarelli L, Compan V, Trillat AC, Hen R. Altered emotional states in knockout mice lacking 5-HT1A or 5-HT1B receptors. Neuropsychopharmacology 1999; 21 Suppl 2:52S-60S.
15. Sramek JJ, Hong WW, Hamid S, Nape B, Cutler NR. Meta-analysis of the safety and tolerability of two dose regimens of buspirone in patients with persistent anxiety. Depress Anxiety 1999; 9:131-4.
16. Chaouloff F. Serotonin, stress and corticoids. J Psychopharmacol 2000; 14:139-51.
17. Van De Kar LD, Bethea CL. Pharmacological evidence that serotonergic stimulation of prolactin release is mediated via the dorsal raphe nucleus. Neuroendocrinology 1982; 35:225-30.
18. Van de Kar LD, Rittenhouse PA, Li Q, Levy AD. Serotonergic regulation of renin and prolactin secretion. Behav Brain Res 1996; 76:203-8.
19. Cowen PJ, Anderson IM, Gartside SE. Endocrinological responses to 5-HT. Ann NY Acad Sci 1990; 600:250-7.
20. Kordon C, Blake CA, Terkel J, Sawyer CH. Participation of serotonin-containing neurons in the suckling-induced rise in plasma prolactin levels in lactating rats. Neuroendocrinology 1973; 13:213-23.
21. Gallo RV, Rabii J, Moberg GP. Effect of methysergide, a blocker of serotonin receptors, on plasma prolactin levels in lactating and ovariectomised rats. Endocrinology 1975; 97:1096-105.
22. Dinan TG, Barry S, Yatham LN, Mobayed M, Brown I. The reproducibility of the prolactin response to buspirone: relationship to the menstrual cycle. Int Clin Psychopharmacol 1990; 5:119-23.
23. Anderson IM, Cowen PJ. Effect of pindolol on endocrine and temperature responses to buspirone in healthy volunteers. Psychopharmacology 1992; 106:428-32.
24. Coccaro EF, Gabriel S, Mahon T, Macaluso J, Siever LJ. Preliminary evidence of a serotonin (5-HT-1-like) component to the prolactin response to buspirone challenge in humans. Arch General Psychiatry 1990; 47:594-5.
25. Gordon ML, Lipton RB, Brown SL, Nakraseine C, Russell M, Pollack SZ et al. Headache and cortisol responses to m-chlorophenylpiperazine are highly correlated. Cephalalgia 1993; 13:400-5.
26. Leone M, Attanasio A, Croci D, Ferraris A, D'Amico D, Grazzi L et al. 5-HT1A receptor hypersensitivity in migraine is suggested by the m-chlorophenylpiperazine test. Neuroreport 1998; 9:2605-8.
27. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain. Cephalalgia 1988; 8 Suppl 7:1-96.
28. McBride A, Ierney H, DeMeo M et al. Effects of age and gender on serotonergic responsivity in normal adults. Biol Psychiatry 1990; 27:1143-55.
29. O'Keane V, O'Hanlon M, Webb M, Dinan TG. D-fenfluramine/prolactin response throughout the menstrual cycle: evidence for an oestrogen-induced alteration. Clin Endocrinol 1991; 34:289-92.
30. Hamik A, Peroutka SJ. 1-(m-Chlorophenyl) piperazine (mCPP) interactions with neurotransmitter receptors in the human brain. Biol Psychiatry 1989; 25:569-75.
31. Pinessi L, Rainero I, Savi L, Valfre W, Limone P, Calvelli P et al. Effect of subcutaneous sumatriptan on plasma growth hormone concentrations in migraine patients. Cephalalgia 2000; 20:223-7.
32. Connor HE, Feniuk W. Migraine, serotonin and sumatriptan. Vasc Med Rev 1992; 3:95-108.
33. Polleri A, Nappi G, Masturzo P, Martignoni E, Murialdo G, Bono G et al. Neuroendocrine approach to headache. In: Critchley M, editors. Advances in Neurology, Vol. 33. New York: Raven Press, 1982: 173-82.
34. Glover V, Ahmed F, Hussein N, Jarman J, Peatfield RC. Central 5-hydroxytryptamine supersensitivity in migraine. In: Ferrari M, Harnett S, editors. Migraine Pharmacology and Genetics. London: Chapman & Hall, 1996: 117-26.
35. Elwan O, Abdella M, El Bayad AB, Hamdy S. Hormonal changes in headache patients. J Neurol Sci 1991; 106:75-81.
36. Murialdo G, Masturzo P, Ferrari ML, Filippi U, De Palma D, Farinini D et al. Thyroid-stimulating hormone and prolactin responses to thyrotropin-releasing hormone in common migraine. Cephalalgia 1987; 7:67-272.
37. Awaki E, Takeshima T, Takahashi K. A neuroendocrinological study in female migraineurs, prolactin and thyroid stimulating hormone responses. Cephalalgia 1989; 9:187-93.
38. Bakheit AM, Behan PO, Dinan TG, Gray CE, O'Keane V. Possible upregulation of hypothalamic 5-hydroxytryptamine receptors in patients with postviral fatigue syndrome. BMJ 1992; 304:1566-7.
39. Dinan TG, Mahmud N, Rathore O, Thakore J, Scott LV, Carr E et al. A double-blind placebo-controlled study of buspirone-stimulated prolactin release in non-ulcer dyspepsia - are central serotoninergic responses enhanced? Alimentary Pharmacol Therapeutics 2001; 15:1613-8.
40. Yap CY, Taylor DA. Involvement of 5-HT2 receptors in the wet-dog shake behaviour induced by 5-hydroxytryptophan in the rat. Neuropharmacology 1983; 22:801-4.
41. Jorgensen H, Knigge U, Warberg J. Effect of serotonin 5-HT1, 5-HT2, 5-HT3 receptor antagonists on the prolactin response to restraint and ether stress. Neuroendocrinology 1992; 56:371-7.
42. Matzen S, Secher NH, Knigge U, Pawelczyk J, Perko G, Iverson H et al. Warberg. Effect of serotonin receptor blockade on endocrine and cardiovascular response to head-up tilt in humans. Acta Physiol Scand 1993; 149:163-76.
43. Gudelsky GA, Koenig JI, Meltzer HY. Thermoregulatory response to serotonin receptor stimulation in the rat. Evidence for opposing roles of 5-HT2 and 5-HT1A receptors. Neuropharmacology 1986; 25:1307-13.
44. Goodwin GM. The effects of antidepressant treatments and lithium upon 5-HT1A receptor function. Prog Neuropsychopharmacol Biol Psychiatry 1989; 13:445-51.
45. Ichikawa J, Meltzer HY. Valproate and carbamazepine increase prefrontal dopamine release by 5-HT1A receptor activation. Eur J Pharmacol 1999; 380:R1-3.
46. Shiah IS. Yatham, Lam RW, Zis AP. Effects of divalproax sodium on 5-HT1A receptor function in healthy human males: hypothermic, hormonal and behavioural responses to ipsapirone. Neuropsychopharmacology 1997; 17:382-90
47. Newman-Tancredi A, Conte C, Chaput C, Verriele L, Audinot-Bouchez V, Lochon S et al. Agonist activity of antimigraine drugs at recombinant human 5-HT1A receptors: potential implications for prophylactic and acute therapy. Naunyn Schmiedebergs Arch Pharmacol 1997; 355:682-8.